Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Betaferon
|
| gptkbp:advocates_for |
informed consent required
|
| gptkbp:analysis |
statistical analysis
|
| gptkbp:analyzes |
Dr. Scott Kopetz
|
| gptkbp:business_model |
institutional review board
|
| gptkbp:clinical_trial |
Phase III
NC T02928224 potentially improves patient outcomes |
| gptkbp:collaborations |
various research institutions
|
| gptkbp:collection |
clinical assessments
|
| gptkbp:committee |
independent committee
|
| gptkbp:criteria |
gptkb:BRAF_V600_E_mutation
prior treatment with BRAF inhibitors |
| gptkbp:events |
minimum of 12 months
|
| gptkbp:finale_date |
response rate
overall survival |
| gptkbp:focuses_on |
BRAF-mutant colorectal cancer
|
| https://www.w3.org/2000/01/rdf-schema#label |
BEACON trial
|
| gptkbp:impact |
guides treatment decisions
|
| gptkbp:is_compared_to |
standard of care
|
| gptkbp:is_protected_by |
parallel assignment
|
| gptkbp:is_studied_in |
completed
randomized controlled trial |
| gptkbp:is_tested_for |
Phase 3
BRAF V600 E |
| gptkbp:launch_date |
2017-01-01
|
| gptkbp:located_in |
gptkb:Europe
gptkb:Asia gptkb:North_America |
| gptkbp:location |
multiple countries
|
| gptkbp:participants |
quality of life
overall survival progression-free survival |
| gptkbp:population |
adult patients
|
| gptkbp:products |
gptkb:binimetinib
cetuximab encorafenib |
| gptkbp:publishes |
peer-reviewed article
|
| gptkbp:receives_funding_from |
gptkb:Company
|
| gptkbp:research |
published in medical journals
advances understanding of BRAF mutations |
| gptkbp:research_focus |
targeted therapy
|
| gptkbp:result |
gptkb:2021
improved overall survival tolerable safety profile |
| gptkbp:safety_features |
adverse events
|
| gptkbp:safety_record |
ongoing throughout study
|
| gptkbp:sponsor |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:student_enrollment |
approximately 600 patients
metastatic disease |
| gptkbp:target_audience |
patients with metastatic colorectal cancer
|
| gptkbp:treatment |
gptkb:binimetinib
cetuximab three treatment groups encorafenib |
| gptkbp:voting_method |
1:1:1 ratio
|
| gptkbp:year |
2019-12-31
2020-12-31 |